vs
California Resources Corp（CRC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是California Resources Corp的1.1倍（$127.1M vs $119.0M），再鼎医药自由现金流更多（$-26.7M vs $-32.0M），过去两年再鼎医药的营收复合增速更高（20.8% vs -46.3%）
加州资源集团是一家美国能源企业，主要在加州开展油气勘探业务。公司注册地为特拉华州，总部位于加州长滩，所持有的加州矿产地块面积是该州私有主体中的最高水平。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CRC vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.1倍
$119.0M
自由现金流更多
ZLAB
多$5.3M
$-32.0M
两年增速更快
ZLAB
近两年复合增速
-46.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $119.0M | $127.1M |
| 净利润 | — | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | -597.5% | -54.6% |
| 净利率 | — | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-8.02 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRCZLAB
| Q1 26 | $119.0M | — | ||
| Q4 25 | $679.0M | $127.1M | ||
| Q3 25 | $715.0M | $115.4M | ||
| Q2 25 | $702.0M | $109.1M | ||
| Q1 25 | $814.0M | $105.7M | ||
| Q4 24 | $826.0M | $108.5M | ||
| Q3 24 | $870.0M | $101.8M | ||
| Q2 24 | $412.0M | $100.1M |
净利润CRCZLAB
| Q1 26 | — | — | ||
| Q4 25 | $12.0M | — | ||
| Q3 25 | $64.0M | $-36.0M | ||
| Q2 25 | $172.0M | $-40.7M | ||
| Q1 25 | $115.0M | $-48.4M | ||
| Q4 24 | $33.0M | — | ||
| Q3 24 | $345.0M | $-41.7M | ||
| Q2 24 | $8.0M | $-80.3M |
毛利率CRCZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率CRCZLAB
| Q1 26 | -597.5% | — | ||
| Q4 25 | 6.9% | -54.6% | ||
| Q3 25 | 13.7% | -42.3% | ||
| Q2 25 | 38.0% | -50.3% | ||
| Q1 25 | 22.9% | -53.3% | ||
| Q4 24 | 8.2% | -62.6% | ||
| Q3 24 | 59.5% | -66.6% | ||
| Q2 24 | 9.2% | -76.0% |
净利率CRCZLAB
| Q1 26 | — | — | ||
| Q4 25 | 1.8% | — | ||
| Q3 25 | 9.0% | -31.2% | ||
| Q2 25 | 24.5% | -37.3% | ||
| Q1 25 | 14.1% | -45.8% | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 39.7% | -40.9% | ||
| Q2 24 | 1.9% | -80.2% |
每股收益（稀释后）CRCZLAB
| Q1 26 | $-8.02 | — | ||
| Q4 25 | $0.21 | $-0.05 | ||
| Q3 25 | $0.76 | $-0.03 | ||
| Q2 25 | $1.92 | $-0.04 | ||
| Q1 25 | $1.26 | $-0.04 | ||
| Q4 24 | $0.87 | $-0.09 | ||
| Q3 24 | $3.78 | $-0.04 | ||
| Q2 24 | $0.11 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $715.5M |
| 总资产 | — | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRCZLAB
| Q1 26 | — | — | ||
| Q4 25 | $132.0M | $689.6M | ||
| Q3 25 | $196.0M | $717.2M | ||
| Q2 25 | $72.0M | $732.2M | ||
| Q1 25 | $214.0M | $757.3M | ||
| Q4 24 | $372.0M | $779.7M | ||
| Q3 24 | $241.0M | $616.1M | ||
| Q2 24 | $1.0B | $630.0M |
总债务CRCZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.2B | — |
股东权益CRCZLAB
| Q1 26 | $2.9B | — | ||
| Q4 25 | $3.7B | $715.5M | ||
| Q3 25 | $3.4B | $759.9M | ||
| Q2 25 | $3.4B | $791.7M | ||
| Q1 25 | $3.5B | $810.8M | ||
| Q4 24 | $3.5B | $840.9M | ||
| Q3 24 | $3.5B | $667.7M | ||
| Q2 24 | $2.1B | $704.2M |
总资产CRCZLAB
| Q1 26 | — | — | ||
| Q4 25 | $7.4B | $1.2B | ||
| Q3 25 | $6.8B | $1.2B | ||
| Q2 25 | $6.7B | $1.2B | ||
| Q1 25 | $6.8B | $1.2B | ||
| Q4 24 | $7.1B | $1.2B | ||
| Q3 24 | $7.1B | $985.3M | ||
| Q2 24 | $4.5B | $987.4M |
负债/权益比CRCZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.57× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-32.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | -26.9% | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $380.0M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CRCZLAB
| Q1 26 | $99.0M | — | ||
| Q4 25 | $235.0M | $-26.0M | ||
| Q3 25 | $279.0M | $-32.0M | ||
| Q2 25 | $165.0M | $-31.0M | ||
| Q1 25 | $186.0M | $-61.7M | ||
| Q4 24 | $206.0M | $-55.8M | ||
| Q3 24 | $220.0M | $-26.8M | ||
| Q2 24 | $97.0M | $-42.2M |
自由现金流CRCZLAB
| Q1 26 | $-32.0M | — | ||
| Q4 25 | $115.0M | $-26.7M | ||
| Q3 25 | $188.0M | $-35.0M | ||
| Q2 25 | $109.0M | $-33.9M | ||
| Q1 25 | $131.0M | $-63.2M | ||
| Q4 24 | $118.0M | $-58.4M | ||
| Q3 24 | $141.0M | $-28.2M | ||
| Q2 24 | $63.0M | $-42.9M |
自由现金流率CRCZLAB
| Q1 26 | -26.9% | — | ||
| Q4 25 | 16.9% | -21.0% | ||
| Q3 25 | 26.3% | -30.4% | ||
| Q2 25 | 15.5% | -31.1% | ||
| Q1 25 | 16.1% | -59.9% | ||
| Q4 24 | 14.3% | -53.8% | ||
| Q3 24 | 16.2% | -27.7% | ||
| Q2 24 | 15.3% | -42.9% |
资本支出强度CRCZLAB
| Q1 26 | — | — | ||
| Q4 25 | 17.7% | 0.5% | ||
| Q3 25 | 12.7% | 2.6% | ||
| Q2 25 | 8.0% | 2.6% | ||
| Q1 25 | 6.8% | 1.5% | ||
| Q4 24 | 10.7% | 2.4% | ||
| Q3 24 | 9.1% | 1.3% | ||
| Q2 24 | 8.3% | 0.7% |
现金转化率CRCZLAB
| Q1 26 | — | — | ||
| Q4 25 | 19.58× | — | ||
| Q3 25 | 4.36× | — | ||
| Q2 25 | 0.96× | — | ||
| Q1 25 | 1.62× | — | ||
| Q4 24 | 6.24× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 12.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
